Mostrar registro simples

AutorSales Junior, Policarpo Ademar
AutorMolina, Israel
AutorMurta, Silvane Maria Fonseca
AutorSanchez-Montalva, Adrian
AutorSalvador, Fernando
AutorOliveira, Rodrigo Correa de
AutorCarneiro, Claudia Martins
Data de acesso2018-03-21T13:27:50Z
Data de disponibilização2018-03-21T13:27:50Z
Data do publicação2017
CitaçãoSALES JUNIOR, Policarpo Ademar et al. Experimental and Clinical Treatment of Chagas Disease: A Review. American Journal of Tropical Medicine and Hygiene, v. 97, n. 5, p. 1289-1303, 2017.pt_BR
ISSN0002-9637pt_BR
URIhttps://www.arca.fiocruz.br/handle/icict/25439
Idiomaengpt_BR
EditorAmerican Society of Tropical Medicine and Hygienept_BR
Direito Autoralrestricted accesspt_BR
Palavras-chaveTrypanosoma cruzipt_BR
Palavras-chaveDoença de Chagaspt_BR
TítuloExperimental and Clinical Treatment of Chagas Disease: A Reviewpt_BR
Tipo do documentoArticle
DOI10.4269/ajtmh.16-0761
Resumo em InglêsChagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a broad range of triatomines and mammalian species, including man. It afflicts 8 million people in Latin America, and its incidence is increasing in nonendemic countries owing to rising international immigration and nonvectorial transmission routes such as blood donation. Since the 1960s, the only drugs available for the clinical treatment of this infection have been benznidazole (BZ) and nifurtimox (NFX). Treatment with these trypanocidal drugs is recommended in both the acute and chronic phases of CD. These drugs have low cure rates mainly during the chronic phase, in addition both drugs present side effects that may result in the interruption of the treatment. Thus, more efficient and better-tolerated new drugs or pharmaceutical formulations containing BZ or NFX are urgently needed. Here, we review the drugs currently used for CD chemotherapy, ongoing clinical assays, and most-promising new experimental drugs. In addition, the mechanism of action of the commercially available drugs, NFX and BZ, the biodistribution of the latter, and the potential for novel formulations of BZ based on nanotechnology are discussed.Taken together, the literature emphasizes the urgent need for new therapies for acute and chronic CD.pt_BR
AfiliaçãoFundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil.pt_BR
AfiliaçãoUniversitat Autonoma de Barcelona. Vall d’Hebron University Hospital. Infectious Diseases Department. PROSICS Barcelona, Barcelona, Spain / Universidade Federal de Ouro Preto. Núcleo de Pesquisas em Ciências Biológicas. Laboratório de Imunopatologia. Ouro Preto, MG, Brasil.pt_BR
AfiliaçãoFundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil.pt_BR
AfiliaçãoUniversitat Autonoma de Barcelona. Vall d’Hebron University Hospital. Infectious Diseases Department. PROSICS Barcelona, Barcelona, Spain.pt_BR
AfiliaçãoUniversitat Autonoma de Barcelona. Vall d’Hebron University Hospital. Infectious Diseases Department. PROSICS Barcelona, Barcelona, Spain.pt_BR
AfiliaçãoFundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil / Universidade Federal de Ouro Preto. Núcleo de Pesquisas em Ciências Biológicas. Laboratório de Imunopatologia. Ouro Preto, MG, Brasil.pt_BR
AfiliaçãoUniversidade Federal de Ouro Preto. Núcleo de Pesquisas em Ciências Biológicas. Laboratório de Imunopatologia. Ouro Preto, MG, Brasil.pt_BR
Palavras-chave em inglêsChagas diseasept_BR
Palavras-chave em inglêsTrypanosoma cruzipt_BR
Data de embargo2060-01-01
xmlui.metadata.dc.subject.ods03 Saúde e Bem-Estar


Arquivos deste item

application/pdf
Nome:
Experimental and Clinical Treatment ...
Tamanho:
7.122Mb
Formato:
application/
Visualizar/Abrir

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples